Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 13, 2023AIDS

Real world use of dolutegravir two drug regimens

View Full Paper
Ask AI
Bookmark
Share

Authors

CBConor BowmanAAAlissa AmbroseTKTanmay Kanitkar

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates high efficacy of dolutegravir two drug regimens in a real-world setting, indicating stability and tolerability.

Key Points

  • This research aims to evaluate the real-world effectiveness and tolerability of dolutegravir-based two drug regimens for treating HIV.
  • Analyzed clinic database from January 15 to October 21.
  • Included demographic and HIV-related data for 620 individuals with complete data.
  • Assessed virological outcomes and side-effects experienced by participants.
  • Nine individuals achieved viral suppression after naïve initiation (100%).
  • 546 out of 552 participants (99.0%) remained suppressed at data censor.
  • Only 1.1% (6 out of 552) experienced virological failure, with one developing triple class resistance.

Cite This Study

Bowman et al. (2023) studied this question.

synapsesocial.com/papers/6a337c8a564550b2400e6bc3https://doi.org/10.1097/qad.0000000000003480
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care2024 · 3 citations
  2. 2Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review2025 · 3 citations
  3. 3Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed2024 · 2 citations
  4. 4Clinical outcomes of switching to dolutegravir/lamivudine dual therapy in people living with HIV: A single‐centre retrospective study2025
  5. 5‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort2026